Ernexa targets Q4 2026 IND filing for ERNA-101 trial in ovarian cancer
Company reported new preclinical safety results supporting a planned IND filing in Q4 2026. Initial clinical data are expected in Q4 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.